Adoptive T cell therapy – CARs, TILs and beyond
Date and time: Tue 05-Nov-2019, 11:00 am-12:30 pm
Programme stream(s): Treatment
Programme session type(s): Parallel session
Speaker: Inge Marie Svane, Copenhagen University Hospital, Herlev, Denmark
Speaker: John Haanen, Netherlands Cancer Institute, Amsterdam
Speaker: Jakub Svoboda, University of Pennsylvania, USA
With FDA, EMA and NHS England approval of CD19 CAR-T cell therapy, CAR-T therapy is set to move into the realms of standard of care in the UK for the first time. This session will review landscape, toxicities and future advances for CAR-T therapies and other forms of adoptive cell therapy (ACT) across both haematological malignancies and in the solid tumour setting. It will also explore some of the many challenges that are associated with scaling up and rolling out these complex therapies.